<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H0DD3929FF3514D278163FC05436E8BAE" public-private="public" key="H" bill-type="olc">
<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 6094 IH: PROTECT Rare Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-10-26</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code>
<congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session>
<legis-num display="yes">H. R. 6094</legis-num>
<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
<action display="yes">
<action-date date="20231026">October 26, 2023</action-date>
<action-desc><sponsor name-id="M001163">Ms. Matsui</sponsor> (for herself, <cosponsor name-id="D000628">Mr. Dunn of Florida</cosponsor>, <cosponsor name-id="T000460">Mr. Thompson of California</cosponsor>, and <cosponsor name-id="K000376">Mr. Kelly of Pennsylvania</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc>
</action>
<legis-type>A BILL</legis-type>
<official-title display="yes">To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition, and for other purposes.</official-title>
</form>
<legis-body id="H526C7D0305C140BF8D6FF56037957504" style="OLC">
<section id="H6525F7570F6745259F0CA88AE97CF8AA" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act</short-title></quote> or the <quote>PROTECT Rare Act</quote>.</text></section> <section id="H13C13FF5D0C344289D334B99F1C46BB9"><enum>2.</enum><header>Coverage of certain drugs used in treatment or management of rare disease or condition</header> <subsection id="H154EFA14E955424FBBD9DEB7511D7FAA"><enum>(a)</enum><header>Medicare</header> <paragraph id="H79812774E0D04ABDA4F5E58210D06578"><enum>(1)</enum><header>In general</header><text>Section 1861(t)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(t)(2)</external-xref>) is amended—</text>
<subparagraph id="HF93C649919C143FCB4F9488C30770780"><enum>(A)</enum><text>in subparagraph (A), by inserting after <quote>regimen</quote> the following: <quote>, or in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States,</quote>; and</text></subparagraph> <subparagraph id="HC985440175BD4AEBB515FCFED6967CD9"><enum>(B)</enum><text>in subparagraph (B)(ii)—</text>
<clause id="HBFAF55983BEE4C009567CF96D59FE76D"><enum>(i)</enum><text>in subclause (I), by striking <quote>, or</quote> at the end and inserting a semicolon;</text></clause> <clause id="H60F4D881946F42908E03F45729D189CF"><enum>(ii)</enum><text>in subclause (II), by striking the period at the end and inserting <quote>; or</quote>; and</text></clause>
<clause id="H99888E1355A949EB91333FEDF6D85455"><enum>(iii)</enum><text>by adding at the end the following new subclause:</text> <quoted-block id="H0FC0C8DA4FF044E8A04C4A9D58249EA9" style="OLC"> <subclause id="H608B71BA2B2B484EA7A78F57870E453A"><enum>(III)</enum><text>in the case of a drug that is used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States, such use is supported by peer-reviewed medical literature, including clinical guidelines, and is not reviewed unfavorably in the compendia described in section 1927(g)(1)(B)(i), or listed as a contraindication in the FDA-approved labeling.</text></subclause><after-quoted-block>.</after-quoted-block></quoted-block></clause></subparagraph></paragraph>
<paragraph id="H4A990B2F7C2F48ABA0FC2B3343FDD425"><enum>(2)</enum><header>Medically accepted uses of covered part d drugs in treating rare conditions</header><text>Section 1860D–2(e)(4)(A) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-102">42 U.S.C. 1395w–102(e)(4)(A)</external-xref>) is amended—</text> <subparagraph id="HED40213EEF884EC083191A1A3ED38C4E"><enum>(A)</enum><text>in clause (i)(II), by striking <quote>and</quote>;</text></subparagraph>
<subparagraph id="H6D8D24E21AEB401AB8C11161239CEF6E"><enum>(B)</enum><text>by redesignating clause (ii) as clause (iii); and</text></subparagraph> <subparagraph id="H9C6074853A2643D885A9B9BA864DA773"><enum>(C)</enum><text>by inserting after clause (i)(II) the following new clause:</text>
<quoted-block style="OLC" id="H9B10BDFDEEDF4202B8B365A542776B57" display-inline="no-display-inline">
<clause id="HA58C20EA641B489CA7FAAFF02A61CB68" commented="no"><enum>(ii)</enum><text display-inline="yes-display-inline">in the case of a covered part D drug used in the treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States, in section 1861(t)(2)(B); and</text></clause><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph> <paragraph id="H338A595C77AE457EA5A0B746DECD8290"><enum>(3)</enum><header>Effective date</header><text>The amendments made by this subsection apply with respect to items and services furnished on or after the date that is 30 days after the date of the enactment of this Act.</text></paragraph></subsection>
<subsection id="HE1A2E1486024495793742360DEBC08FE"><enum>(b)</enum><header>Medicaid</header>
<paragraph id="HF0AC5FAF6EB44F85B6999374118FC65A"><enum>(1)</enum><header>In general</header><text>Section 1927(k)(6) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(k)(6)</external-xref>) is amended to read as follows:</text> <quoted-block style="OLC" id="HA5D922B58D6C42FFB2C481A3CF6B9241" display-inline="no-display-inline"> <paragraph id="HB4115D932E2343679D2AB0D4F517EE4C"><enum>(6)</enum><header>Medically accepted indication</header><text display-inline="yes-display-inline">The term <term>medically accepted indication</term> means any use for a covered drug—</text>
<subparagraph id="HA2591E1FF48B404A81B7AC42ED16F4E1"><enum>(A)</enum><text display-inline="yes-display-inline">which is approved under the Federal Food, Drug, and Cosmetic Act;</text></subparagraph> <subparagraph id="H79AA3806B7A74D248768F0BDB9DFABF4"><enum>(B)</enum><text display-inline="yes-display-inline">which is supported by one or more citations included or approved for inclusion in any of the compendia described in subsection (g)(1)(B)(i); or</text></subparagraph>
<subparagraph id="H354CC012B27342138F5696C75E4F303A"><enum>(C)</enum><text display-inline="yes-display-inline">in the case of a drug used to treat or manage a disease or condition affecting 200,000 or fewer individuals in the United States—</text> <clause id="HA1255430643C4CA9AC936C5D6649F222"><enum>(i)</enum><text display-inline="yes-display-inline">the use of such drug is supported by peer-reviewed medical literature, including clinical guidelines; and</text></clause>
<clause id="H873D999E35B147E7940DF62764263348"><enum>(ii)</enum><text display-inline="yes-display-inline">is not reviewed unfavorably in the compendia described in subsection (g)(1)(B)(i), or listed as a contraindication in the FDA-approved labeling.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph> <paragraph id="HEE0BEC4CD7F44BAB9CC82D6F5856F8F5" commented="no"><enum>(2)</enum><header>Conforming amendment</header><text>Section 1927(d)(4)(C) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1396r-8">42 U.S.C. 1396r–8(d)(4)(C)</external-xref>) is amended by striking <quote>compendia</quote> and inserting <quote>sources</quote>.</text></paragraph>
<paragraph id="HD5E753E8804448CCB0297CF6B3E378B1"><enum>(3)</enum><header>Effective date</header><text>The amendments made by this subsection apply with respect to covered outpatient drugs furnished on or after the date that is 30 days after the date of the enactment of this Act.</text></paragraph></subsection> <subsection id="H2BFFDD3DD33A47459FB3F2524ADE3354"><enum>(c)</enum><header>Private health insurance</header> <paragraph id="HAEC8A13FFC3F4452BE70F58F0D170F60"><enum>(1)</enum><header>In general</header><text>Subpart II of part A of title XXVII of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-19">42 U.S.C. 300gg–19</external-xref>) is amended by adding at the end the following new section:</text>
<quoted-block id="HC8E51D858BE54CAABC9B34AF6D8218FE" style="OLC">
<section id="HE5E750E84E714DD5AE8F0FACD788839A" commented="no"><enum>2730.</enum><header>Expedited processes for review associated with certain drugs used in treatment or management of a rare disease or condition</header><text display-inline="no-display-inline">A group health plan or a health insurance issuer offering group or individual health insurance coverage shall provide a mechanism for expedited formulary exception, reconsideration, and appeal of any denial of coverage for a drug or biological—</text> <paragraph id="H8FD37F942C434253A1BF5986DFB8C824" commented="no"><enum>(1)</enum><text>approved by the Food and Drug Administration;</text></paragraph>
<paragraph id="H874D788E4A48421EB839DB1EC58199DC" commented="no"><enum>(2)</enum><text>for which the use is related to treatment or management of a disease or condition affecting 200,000 or fewer individuals in the United States; and</text></paragraph> <paragraph id="HC72E7A7E170A4444B33ED74E45418303" commented="no"><enum>(3)</enum><text display-inline="yes-display-inline">the use of which is supported by the FDA-approved label or peer-reviewed literature, including clinical guidelines, and that is not reviewed unfavorably in the compendia described in section 1927(g)(1)(B)(i)) of the Social Security Act or listed as a contraindication in the FDA-approved labeling.</text></paragraph></section><after-quoted-block>.</after-quoted-block></quoted-block></paragraph>
<paragraph id="H3087BF8BA82D4411BE7E0976FF6337B7"><enum>(2)</enum><header>Effective date</header><text>The amendment made by this subsection applies with respect to plan years beginning on or after the date that is 30 days after the date of the enactment of this Act.</text></paragraph></subsection></section> </legis-body> </bill> 

